

June 26, 2019

Consulting Agreement with Dr. Jerry Cagle for Clinical Trials of RBM-007 for Treating Age-Related Macular Degeneration

We are pleased to announce that we have entered into consulting agreement with Dr. Jerry Cagle, former Senior Vice President of Alcon R&D and Chief Scientific Officer. As a member of the scientific advisory board of RIBOMIC, he will provide us with professional expertise for product development of our lead compound RBM-007 for treating age-related macular degeneration.

Yusuf Ali, Ph.D., CEO of RIBOMIC USA Inc., commented: *"I am excited to welcome Dr. Cagle to our scientific advisory board. His extensive product development and industry experience, particularly in various ophthalmic disease areas will be key to leverage our unique aptamer platform. We expect Jerry's expertise to be valuable as we further develop our lead compound RBM-007, currently in clinical trial for the potential treatment of wet Age-related Macular Degeneration".*

On his appointment, Dr. Cagle added: *"I look forward with enthusiasm to collaborating with the RIBOMIC Team in advancing this innovative therapy for the treatment of wet AMD. The novel activities of RBM-007, as an anti-angiogenic and anti-fibrotic, address unmet needs among products currently available for treatment of this important disease."*

Profile of Jerry Cagle, Ph.D.

Dr. Jerry Cagle began his career as an academic as Faculty at The Ohio State University in Columbus. Thereafter, for more than three decades, he served as a member of Alcon's Research and Development Team. During this period, Dr. Cagle was responsible, at one time or another, for all essential scientific functions of R & D at Alcon, including pharma, surgical devices (IOLs and surgical machines) and contact lenses/lens care. He worked directly with and supervised key departments that contribute to new products, including respective Research groups, as well as Product Development areas of pharmaceuticals, toxicology, pharmacokinetics, analytical chemistry, biostatistics, clinical research and the polymer sciences and engineering functions associated with medical instrument development. During his tenure at Alcon, he worked closely with Regulatory Affairs and for several years he was VP of Alcon's Global Regulatory Department. In the mid-1990's, Dr. Cagle was named Senior Vice President of Alcon R&D and Chief Scientific Officer. Dr. Cagle has been honored by the Texas Society to Prevent Blindness as its "Person of Vision."